bioage ipo news - Search News

BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq

California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a weight loss drug.

Reuters on MSN · 2d

Obesity drug developer BioAge Labs aims up to $640 million valuation in upsized US IPO

(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.

Seeking Alpha on MSN · 1d

Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO

Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11,000,000 shares of its common stock at a public offering price of $18.00 per share.

IPO, Ryan Reynolds and MNTN

Inc · 2h

Ryan Reynolds's MNTN Explores Going Public, as the IPO Market Shows Signs of Thawing

After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, including Reynolds' MNTN.

Fortune · 5h

Ryan Reynolds’ ad platform seeks IPO with Morgan Stanley’s help

MNTN builds advertising software that helps brands promote themselves through campaigns on connected TVs.

Bloomberg on MSN · 6h

Ryan Reynolds’s MNTN Is Said to Tap Morgan Stanley for 2025 IPO

MNTN, a connected TV advertising platform that counts Hollywood star Ryan Reynolds as its chief creative officer, has picked Morgan Stanley to work on an initial public offering, according to people familiar with the matter.

FierceBiotech1d

BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq

BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...

BioAge seeks nearly $200 million in initial public offering

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Weight-loss drug developer BioAge raises $198 mln in U.S. IPO

BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the targeted range at $18 per share, the weight-loss drug developer said on Wednesday.

Bioage Labs, Inc IPOs Tomorrow, Here's What You Need To Know

BioAge Labs, Inc BIOA IPO will take place September, 26 on the NASDAQ exchange under the ticker BIOA. The company is offering ...

1don MSN

BioAge, BKV shares end their first trading day flat after earlier gains

Obesity-drug developer BioAge jumps nearly 30% while Texas-based Barnett Shale driller BKV posts smaller gain.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics